Drug Profile
HTLV-I vaccine - Kyushu University
Latest Information Update: 24 Jul 2001
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Cancer vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HTLV-I infections
Most Recent Events
- 24 Jul 2001 No-Development-Reported for HTLV-I infections in Japan (Unknown route)
- 01 Mar 1995 Preclinical development for HTLV-I infections in Japan (Unknown route)